Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Reexamination Certificate
2005-03-01
2005-03-01
Pryor, Alton N. (Department: 1616)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
C424S489000, C424S490000, C514S015800
Reexamination Certificate
active
06861070
ABSTRACT:
A therapeutic agent for voiding dysfunction associated with neurogenic bladder where said agent contains tamsulosin or a pharmaceutically acceptable salt thereof.
REFERENCES:
patent: 4703063 (1987-10-01), Imai et al.
patent: 4987152 (1991-01-01), Imai et al.
patent: 5843472 (1998-12-01), Ma et al.
patent: 6071882 (2000-06-01), Engel et al.
patent: 1282077 (1992-03-01), None
patent: 0 034 432 (1984-04-01), None
patent: 0 416 804 (1991-03-01), None
patent: 0 194 838 (1993-06-01), None
patent: 799619 (1997-10-01), None
patent: 1020190 (2000-07-01), None
patent: 56-110665 (1981-09-01), None
patent: 62-114952 (1987-05-01), None
patent: 3-24014 (1991-02-01), None
patent: 2000-169373 (2000-06-01), None
patent: 2001-114679 (2001-02-01), None
patent: 2001-288115 (2001-10-01), None
patent: WO 9824791 (1998-06-01), None
patent: WO 0000187 (2000-01-01), None
MC Michel et al., “Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms”, Prostate Cancer and Prostatic Diseases, vol. 1 (1998), pp. 332-335.
P. Abrams et al., “A dose-ranging study of the efficacy and safety of tamsulosin, the first prostate-selective α1A-adrenoceptor antagonist*, in patients with benign prostatic obstruction (symptomatic benign prostatic hyperplasia)”, British Journal of Urology, vol. 80, (1997), pp. 587-596.
J.M. Buzelin et al., “Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia)”, British Journal of Urology, vol. 80 (1997), pp 597-605.
P. Abrams et al., “Tamsulosin, a selective α1c-adrenoceptor* antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH)”, British Journal of Urology, vol. 76 (1995), pp. 325-336.
Kosaku Yasuda et al., “The Effect of Urapidil on Neurogenic Bladder: A Placebo Controlled Double-Blind Study”, The Journal of Urology, vol. 156, pp. 1125-1130, Sep. 1996.
Michel Perrigot et al., “Effect of Intravenous Alfuzosin on Urethral Pressure in Patients with Neurogenic Bladder Dysfunction”, Neurourology and Urodynamics vol. 15, pp. 119-131 (1996).
Seigo Hiraga et al., “Usefulness and Safety of Bunazosin Hydrochloride in Neurogenic Bladder After Prolonged Administration”, Hinyokika Kito. Acta Urologica Japonica, vol. 38, No. 2, pp. 255-263 (1992).
Yukie Takimoto et al., “Clinical Effect of New α-Adrenergic Blocker on Micturition Disturbance of Neurogenic Bladder and Lower Urinary Tract Obstruction”, Hinyokika Kito. Acta Urologica Japonica, vol. 29, No. 2, pp. 255-263, 1983.
Momokazu Gotoh et al., “Effects of Alpha-1-Blocking Agent in the Treatment of Detrusor Sphincter Dyssynergia”, Nippon Hinyokika Gakkai Zasshi.Japanese Journal or Urology, vol. 81, No. 12, pp. 1877-1883 (1990).
Martin C. Michel et al., “Tamsulosin: Real Life Clinical Experience in 19,365 Patients”, European Urology, vol. 34 (suppl 2) (1998), pp. 37-45.
C. de Mey et al., “A Double-Blind Comparison of Terazosin and Tamsulosin on Their Differential Effects on Ambulatory Blood Pressure and Noctural Orthostatic Stress Testing”, European Urology, vol. 33 (1998), pp. 481-488.
C.R. Chapple et al., “Tamsulosin 0.4 mg Once Daily: Tolerability in Older and Younger Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (Symptomatic BPH)”, European Urology, vol. 32 (1997), pp. 462-470.
S. Kondo et al., “Quantitative Analysis of Adrenergic Alpha-1 and Alpha-2 Receptors in Human Prostatic Urethral Tissue,”British Journal of Urology, vol. 72, (1993), pp. 68-73.
USP Dictionary of USAN and International Drug Names (1997), p. 689.
U.S. Appl. No. 10/470,550, filed Jul. 30, 2003, Shimoyama et al.
Fitspatrick, J.M. Facts and future lines of research in lower urinary tract imptoms in men and women: an overview of the role of α1-Adrenoceptor antagonists. BJU International, 85 (Suppl. 2), pp. 1-5 (2000).
Williams, T.J., et al., In Vitro α1-adrenoceptor pharmacology of Ro 70-0004 and RS-100329, novel α1A-Adrenoceptor selective antagonists. British Journal of Pharmacology, 127, pp. 252-258 (1999).
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
Pryor Alton N.
Yamanouchi Pharmaceutical Co. Ltd.
LandOfFree
Medicinal compositions for treating evacuatory insufficiency does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Medicinal compositions for treating evacuatory insufficiency, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Medicinal compositions for treating evacuatory insufficiency will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3452462